ES2657266T3 - Medios y procedimientos para la predicción de respuesta al tratamiento de la hepatitis B - Google Patents

Medios y procedimientos para la predicción de respuesta al tratamiento de la hepatitis B Download PDF

Info

Publication number
ES2657266T3
ES2657266T3 ES13712387.3T ES13712387T ES2657266T3 ES 2657266 T3 ES2657266 T3 ES 2657266T3 ES 13712387 T ES13712387 T ES 13712387T ES 2657266 T3 ES2657266 T3 ES 2657266T3
Authority
ES
Spain
Prior art keywords
hepatitis
carnitine
patient
hbsag
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13712387.3T
Other languages
English (en)
Spanish (es)
Inventor
Hendrik Willem REESINK
Louis JANSEN
Neeltje Akke KOOTSTRA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Academisch Medisch Centrum
Original Assignee
Academic Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academic Medical Center filed Critical Academic Medical Center
Application granted granted Critical
Publication of ES2657266T3 publication Critical patent/ES2657266T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
    • C12Q2535/131—Allele specific probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES13712387.3T 2012-03-19 2013-03-19 Medios y procedimientos para la predicción de respuesta al tratamiento de la hepatitis B Active ES2657266T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12160199 2012-03-19
EP12160199 2012-03-19
EP12186188 2012-09-26
EP12186188 2012-09-26
PCT/NL2013/050204 WO2013141705A2 (en) 2012-03-19 2013-03-19 Means and methods for response prediction of hepatitis b treatment

Publications (1)

Publication Number Publication Date
ES2657266T3 true ES2657266T3 (es) 2018-03-02

Family

ID=47997743

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13712387.3T Active ES2657266T3 (es) 2012-03-19 2013-03-19 Medios y procedimientos para la predicción de respuesta al tratamiento de la hepatitis B

Country Status (9)

Country Link
US (2) US20150044167A1 (enExample)
EP (1) EP2828401B1 (enExample)
BR (1) BR112014023296A2 (enExample)
ES (1) ES2657266T3 (enExample)
HK (1) HK1206791A1 (enExample)
IN (1) IN2014MN01989A (enExample)
MX (1) MX2014011256A (enExample)
RU (1) RU2640256C2 (enExample)
WO (1) WO2013141705A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105829548A (zh) * 2013-12-17 2016-08-03 豪夫迈·罗氏有限公司 用于hbv治疗反应的生物标记物
EP3322820A1 (en) * 2015-07-15 2018-05-23 H. Hoffnabb-La Roche Ag Biomarkers for hbv treatment response
CN109504763B (zh) * 2018-12-17 2020-09-04 北京三元基因药业股份有限公司 用于预测α干扰素治疗乙肝患者疗效的分子标记
UA129589C2 (uk) 2018-12-19 2025-06-11 Лео Фарма А/С Аніліди амінокислот як низькомолекулярні модулятори il-17
CN115267193B (zh) * 2022-09-20 2022-12-27 北京大学 用于判断生物样本中HBsAg来源的方法及系统和用途

Also Published As

Publication number Publication date
HK1206791A1 (en) 2016-01-15
MX2014011256A (es) 2015-07-14
US20150044167A1 (en) 2015-02-12
IN2014MN01989A (enExample) 2015-07-10
WO2013141705A3 (en) 2013-12-05
BR112014023296A2 (pt) 2019-09-24
US20180044735A1 (en) 2018-02-15
RU2014142009A (ru) 2016-05-10
EP2828401A2 (en) 2015-01-28
EP2828401B1 (en) 2017-10-25
WO2013141705A2 (en) 2013-09-26
RU2640256C2 (ru) 2017-12-27

Similar Documents

Publication Publication Date Title
Halgand et al. Hepatitis B virus pregenomic RNA in hepatocellular carcinoma: a nosological and prognostic determinant
Chan et al. Hepatitis B surface antigen quantification: why and how to use it in 2011–a core group report
ES2657266T3 (es) Medios y procedimientos para la predicción de respuesta al tratamiento de la hepatitis B
Deng et al. The genetic polymorphism down‐regulating HLA‐DRB1 enhancer activity facilitates HBV persistence, evolution and hepatocarcinogenesis in the Chinese Han population
US20220202770A1 (en) Composition for treating hepatitis b, and method for evaluating replication activity of hepatitis b virus
Buti et al. Tenofovir discontinuation after long-term viral suppression in HBeAg negative chronic hepatitis B. Can HBsAg levels be useful?
CN115066505A (zh) 生物标记物及其在治疗慢性乙型肝炎感染中的用途
Hao et al. Naturally occurring deletion/insertion mutations within HBV whole genome sequences in HBeAg-positive chronic hepatitis B patients are correlated with baseline serum HBsAg and HBeAg levels and might predict a shorter interval to HBeAg loss and seroconversion during antiviral treatment
Wang et al. Integrating nested PCR with high-throughput sequencing to characterize mutations of HBV genome in low viral load samples
Heo et al. A 96-week randomized trial of switching to entecavir in chronic hepatitis B patients with a partial virological response to lamivudine
Wang et al. Viral quasispecies of hepatitis B virus in patients with YMDD mutation and lamivudine resistance may not predict the efficacy of lamivudine/adefovir rescue therapy
Xu et al. The central nervous system is a potential reservoir and possible origin of drug resistance in hepatitis B infection
Naderi et al. Host and Viral Factors Influencing Chronic Hepatitis B Infection Across Three Generations in a Family
Wei et al. Genetic variation in FCER1A predicts peginterferon alfa‐2a‐induced hepatitis B surface antigen clearance in East Asian patients with chronic hepatitis B
US20170283889A1 (en) Biomarkers for HBV treatment response
Li et al. Detection of primary YMDD mutations in HBV-related hepatocellular carcinoma using hybridization-fluorescence polarization
JP2017502663A (ja) Ｈｂｖ治療反応に関するバイオマーカー
Yuan et al. ABCC4, ABCC5 and SLC28A1 polymorphisms: host genome on responses of chronic hepatitis B patients with entecavir treatment
Kim et al. Phylogenetic analyses of HBV pre-s/s genes in mother-child pairs with long-term infection by presumed vertical transmission
Kim et al. Locked nucleic acid real-time polymerase chain reaction method identifying two polymorphisms of hepatitis B virus genotype C2 infections, rt269L and rt269I
Hsu et al. Hepatitis B Virus Covalently Closed Circular DNA Predicts Postoperative Liver Cancer Metastasis Independent of Virological Suppression. Cancers (Basel). 2021; 13 (3)
HK40079722A (en) Biomarkers and uses thereof in the treatment of chronic hepatitis b infection
JP2009159844A (ja) Ｂ型肝炎ウイルス量が低下する可能性を予測する方法
JP6841397B2 (ja) Ｂ型肝炎患者の臨床経過を予測する方法
Liu et al. Association between polymorphism of the cyclin E1 gene and susceptibility to hepatocellular carcinoma in Chinese Han population of Hubei